AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN DIEGO -- A single, 2-g dose of metronidazole given orally for the treatment of bacterial vaginosis resulted in a clinical cure rate of 65% and a therapeutic cure rate of 25% at 3 months, results from the largest study of its kind have shown.
"The data about long-term outcomes in women with bacterial vaginosis treated with single-dose metronidazole are very limited," Dr. Harold C. Wiesenfeld said at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology. "There are no long-term studies, [and] all of the published treatment trials to date involved no more than 100 women."
Recommended treatment for bacterial vaginosis (BV) includes both oral and topical metronidazole and clindamycin. "Unfortunately, these regimens are far from ideal, with up to a 40% failure rate 1 month following treatment." Dr. Wiesenfeld said.
He and his associates conducted an observational cohort study of women who presented with pelvic infections at ambulatory sites in Pittsburgh during 1998-2000. Inclusion criteria included women aged 15-30 years who met at least three out of four Amsel criteria for BV. Exclusion criteria included pregnancy, recent antibiotic use, recent gynecologic surgery, having an IUD, or women whose first follow-up was more than 6 months from enrollment.
All women underwent pelvic exam, microbiologic tests of vaginal fluid, and cervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae. All took a single, 2-g dose of metronidazole, for BV, plus a 1-g dose of azithromycin and a 400-mg dose of cefixime, for empiric treatment of cervicitis. A follow-up evaluation was conducted a mean of 15 weeks after treatment in ...
Source: HighBeam Research, BV follow-up at 3 months; Single-dose metronidazole: 65% clinical...